Back to search results

Peer Support for HIV Treatment and Prevention (PUSH) Study

This study is looking at how a peer support program called "Peer Activate-LAI" can help people with HIV or those at high risk for HIV to stick to their long-acting injectable HIV treatment or prevention (LAI-PrEP/ART). This program involves peer recovery specialists who help with problem-solving and behavioral activation. You might be able to join if you are 18 or older, have HIV or are at high risk for it, and meet specific criteria for Cabotegravir-LA or Cabotegravir (CAB) treatment. The study aims to see if Peer Activate-LAI helps people take all their scheduled injections over 12 months. This study is currently recruiting 186 participants, but its overall status is unclear.

Study design
This study is a randomized trial involving 186 participants. It compares the Peer Activate-LAI program to standard care for HIV treatment or prevention.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is measured at 12 months, which suggests participants will be followed for at least that long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06501781

Peer Behavioral Activation Utilization to Improve Substance Use and HIV Outcomes in People Receiving Long Acting Injectable-PrEP/ART (PUSH)

Recruiting
NAAges 18–88Interventional
University of Maryland, Baltimore
~186 participants
Updated 2025-10-31 on ClinicalTrials.gov
What's tested:Peer Activate-LAIStandard of Care HIV treatment or prevention with LAI-PrEP/ART

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
LAI-PrEP/ART Complete Adherence
Measured over 12 months

Conditions

HIV Infections
Substance Use

Explore related trials

HIV InfectionSubstance Use

Where it's being run

2 sites across 2 states
District of Columbia1
Maryland1

Who to contact

Elana Rosenthal, MD
[email protected]
240-367-4157
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or older
Able and willing to sign informed consent
HIV status:
Meeting indications for treatment based on Cabotegravir-LA (HIV negative) or Cabotegravir (CAB) and Rilpivirine (RPV)-LA (HIV positive) prescribing information
Moderate substance use, defined as a (World Health Organization Alcohol, Smoking and Substance Involvement Screening Test) WHO-ASSIST score of ≥4 for certain drugs (cocaine, amphetamines, inhalants, sedatives, hallucinogens, or opioids) or ≥11 for alcohol

Exclusion

Contraindications to Cabotegravir-LA (HIV-) or Cabotegravir (CAB) and Rilpivirine (RPV)-LA (HIV+) use based on prescribing information or other medical/psychiatric conditions that may interfere with study participation
Pregnant or breastfeeding

What this trial measures

  • LAI-PrEP/ART Complete Adherence12 months

    Defined as receiving all 6 LAI maintenance doses within the +/-7 day window. Unit of Measure: Binary (Yes/No)